Drug intelligence / Profile preview

Shenyuan Yiqi Huoxue

Development stage: Unknown
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Shenyuan Yiqi Huoxue is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University. It is primarily administered as a capsule and is designed based on the TCM therapeutic principle of "Yiqi Huoxue," which focuses on supplementing Qi and promoting blood circulation to resolve stasis. The drug is investigated for its potential to treat cardiovascular conditions, specifically ischemic cardiomyopathy and unstable angina pectoris. Clinical studies have evaluated its efficacy in improving cardiopulmonary exercise capacity, mitochondrial metabolic function, and overall quality of life in patients with chronic heart disease.

Other names: Shenyuan Yiqi Huoxue Capsule参元益气活血胶囊

Beyond the preview

Go deeper on Shenyuan Yiqi Huoxue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenyuan Yiqi Huoxue.

Explore the full profile